by Neoteryx, on January 26,2023
An article in The Stanford Daily from Stanford University in California highlights new research led by Michael Snyder, PhD, Stanford Genetics department chair and senior author of the study paper …
Read Storyby Neoteryx, on January 20,2023
Combining artificial intelligence (AI) with other medical diagnostic technologies and remote blood microsampling devices is a winning recipe for continued global health innovation in the near future, predicts Stephen Tomisich, …
Read Storyby Neoteryx, on December 15,2022
December 2022 — Neoteryx, a brand of Trajan Scientific and Medical that provides remote specimen collection and microsampling devices, recently launched a Research Support Program that enables researchers to test …
Read Storyby Neoteryx, on November 2,2022
Polaris Dawn Crew Collects Blood Samples Using Microsampling Devices to Help Scientists Study Effects of Prescription Drugs on Humans During Spaceflight November 2022 — Neoteryx, the microsampling brand of Trajan …
Read Storyby Neoteryx, on October 31,2022
October 31, 2022 — Fianostics GmbH in Austria has launched new COVID-19 antibody test kits that include Mitra® devices from Neoteryx, the microsampling brand of Trajan Scientific and Medical. Fianostics …
Read StoryThe latest product releases, company news and microsampling industry updates from Neoteryx.
If you don’t find the information & assets you need via the buttons below, please contact us here: press@neoteryx.com
Contact Us
Trajan Scientific Americas Inc.
This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Mitra® devices are intended as a specimen collector and for the storage and transport of blood. They are CE-IVD in the UK and EU, a Class 1 IVD in Australia, Brazil & China, Class B in South Africa, and registered with health agencies in Canada and Ukraine.
In the USA, Mitra devices are supplied as a Research-Use Only (RUO) product, to assist in method development, other research-related and non-diagnostic activities. Mitra has not been validated for use with any diagnostic testing. The suitability of Mitra for any analytical application must be evaluated and validated by the laboratory or research institute in a manner consistent with local regulatory requirements.
hemaPEN® is supplied for therapeutic or IVD use in Australia, New Zealand, UK, EU and USA only: ARTG number: 280007; CE mark, general IVD; US FDA number: D410490. Outside of the territories listed above, the hemaPEN is supplied for research use only (RUO) and not for therapeutic or diagnostic use.
Mitra®, VAMS® & hemaPEN® are registered trademarks owned by entities in the Trajan Group.
Copyright © 2022. All rights reserved.